Cytokinetics, Incorporated (38)

Browse by Contract Category

Contracts

Description of Director Compensation (Filed With SEC on November 4, 2022)
Indenture, dated as of July 6, 2022, between Cytokinetics, Incorporated and U.S. Bank Trust Company, National Association, as trustee (Filed With SEC on July 6, 2022)
Third Amendment to Lease, dated January 26, 2021, by and between the Company and KR Oyster Point 1, LLC (Filed With SEC on February 25, 2022)
License and Collaboration Agreement, dated December 20, 2021, by and between the Company and Ji Xing Pharmaceuticals Limited (Filed With SEC on February 25, 2022)
Fast Skeletal Regulatory Activator Agreement, dated April 23, 2020, by and between the Company and Astellas Pharma Inc (Filed With SEC on August 10, 2020)
Common Stock Purchase Agreement, dated December 20, 2021, by and between the Company and RTW Innovation Master Fund, Ltd (Filed With SEC on February 25, 2022)
Common Stock Purchase Agreement, dated December 20, 2021, by and between the Company and RTW Master Fund, Ltd (Filed With SEC on February 25, 2022)
Common Stock Purchase Agreement, dated December 20, 2021, by and between the Company and RTW Venture Fund Limited (Filed With SEC on February 25, 2022)
Development Funding Loan Agreement, dated January 7, 2022, by and among Royalty Pharma Development Funding, LLC and the Company (Filed With SEC on February 25, 2022)
Amendment No. 1 to Royalty Purchase Agreement, dated January 7, 2022, by and between the Company and RPI Finance Trust (Filed With SEC on February 25, 2022)
Revenue Participation Right Purchase Agreement, dated January 7, 2022, by and between the Company and Royalty Pharma Investments 2019 ICAV (Filed With SEC on February 25, 2022)
Amended and Restated 2004 Equity Incentive Plan (Filed With SEC on November 5, 2021)
Fourth Amendment to Loan and Security Agreement, dated June 30, 2021, by and among the Company, Oxford Finance LLC and Silicon Valley Bank (Filed With SEC on November 5, 2021)
Eighth Amendment to Lease, dated May 18, 2021, by and between the Company and Britannia Pointe Grand Limited Partnership (Filed With SEC on August 6, 2021)
Underwriting Agreement, dated as of July 20, 2021, by and among Cytokinetics, Incorporated, J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC (Filed With SEC on July 21, 2021)
Letter Agreement, dated December 23, 2020, by and between Company and Astellas amending the License and Collaboration Agreement for Other Skeletal Sarcomere Activators, dated... (Filed With SEC on February 26, 2021)
Second Amendment to Lease, dated January 26, 2021, by and between the Company and KR Oyster Point 1, LLC (Filed With SEC on February 26, 2021)
First Amendment to Lease, dated May 12, 2020, by and between the Company and KR Oyster Point 1, LLC (Filed With SEC on February 26, 2021)
Third Amendment to Loan and Security Agreement, dated July 16, 2020, by and among the Company, Oxford Finance LLC and Silicon Valley Bank (Filed With SEC on November 6, 2020)
Form of Common Stock Purchase Agreement, dated July 14, 2020 (Filed With SEC on November 6, 2020)
Funding Agreement, dated July 14, 2020, by and between the Company and Dolya Holdco 19 Designated Activity Company (Filed With SEC on November 6, 2020)
License and Collaboration Agreement, dated July 14, 2020, by and between the Company and Ji Xing Pharmaceuticals Limited (Filed With SEC on November 6, 2020)
Royalty Purchase Agreement, dated July 14, 2020, by and between the Company and Dolya Holdco 19 Designated Activity Company (Filed With SEC on November 6, 2020)
Underwriting Agreement, dated as of July 16, 2020, by and among Cytokinetics, Incorporated, Goldman Sachs & Co. LLC, Piper Sandler & Co. and Cantor Fitzgerald & Co (Filed With SEC on July 17, 2020)
Description of Securities (Filed With SEC on March 4, 2020)
Compensation Information for the Companys Named Executive Officers (Filed With SEC on February 28, 2020)
Second Amendment to Loan and Security Agreement, dated as of November 7, 2019, by and among the Company, Oxford Finance LLC and Silicon Valley Bank (Filed With SEC on November 13, 2019)
First Amendment to Loan and Security Agreement, dated as of November 6, 2019, by and among the Company, Oxford Finance LLC and Silicon Valley Bank (Filed With SEC on November 13, 2019)
First Supplemental Indenture, dated November 13, 2019, between the Company and U.S. Bank National Association, as Trustee (including the form of 4.00% Convertible Senior Note due... (Filed With SEC on November 13, 2019)
Base Indenture, dated November 13, 2019, between the Company and U.S. Bank National Association, as Trustee (Filed With SEC on November 13, 2019)
Underwriting Agreement, dated November 7, 2019, by and between the Company and Morgan Stanley & Co. LLC as representative of the several underwriters named therein (Filed With SEC on November 13, 2019)
Seventh Amendment to Lease, dated July 11, 2019, by and between the Company and Britannia Pointe Grand Limited Partnership (Filed With SEC on November 1, 2019)
Form of Warrant Issuable to Oxford Finance LLC (Filed With SEC on August 9, 2019)
Loan and Security Agreement, dated as of May 17, 2019, by and among the Company, Oxford Finance LLC and Silicon Valley Bank (Filed With SEC on August 9, 2019)
Form of Warrant Issuable to Silicon Valley Bank (Filed With SEC on August 9, 2019)
Amendment No. 8, dated November 30, 2016, to the Collaboration and Option Agreement by and between the Company and Amgen Inc (Filed With SEC on March 7, 2019)
Amendment No. 9, dated February 6, 2019, to the Collaboration and Option Agreement by and between the Company and Amgen Inc (Filed With SEC on March 7, 2019)
Controlled Equity Offering Sales Agreement, dated as of March 6, 2019, by and between the Company and Cantor Fitzgerald & Co (Filed With SEC on March 7, 2019)